Windtree Therapeutics, Inc. (Formerly Known As Discovery Laboratories, Inc.)
2600 Kelly Road
Warrington
Pennsylvania
18976
United States
Tel: 215-488-9300
Fax: 215-488-9301
Website: http://www.discoverylabs.com/
406 articles about Windtree Therapeutics, Inc. (Formerly Known As Discovery Laboratories, Inc.)
-
Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives
1/31/2024
Windtree Therapeutics, Inc. today announced that it has engaged Ladenburg Thalmann & Co. Inc. (“Ladenburg”) to evaluate strategic alternatives for the Company with the goal of maximizing stockholder value.
-
Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company
1/25/2024
Windtree Therapeutics, Inc. announced that the Company entered an Exchange and Termination Agreement with affiliates of Deerfield Management Company pursuant to which Deerfield has agreed to terminate its rights under the Company’s 2017 Exchange and Termination Agreement to receive up to $15,000,000 in development and commercial milestone payments associated with AEROSURF®.
-
Windtree Therapeutics Announces License Agreement with Lee’s Pharmaceuticals to Develop and Commercialize Istaroxime, Dual Mechanism SERCA2a Activators and Rostafuroxin for Greater China / Asia Pacific Region
1/17/2024
Windtree to receive potential future milestones up to $138MM plus up to low double digit royalties and full coverage for all development, manufacturing, regulatory and commercialization costs for products in the licensed territory.
-
Windtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a Activator
1/2/2024
Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT) today announced new preclinical data on the Company’s lead product candidate, istaroxime, and another preclinical pipeline drug candidate, CVie-216, showing reductions in ventricular arrythmias in a rat heart model of diabetes with restricted and restored coronary blood flow induced injury.
-
Windtree Therapeutics Announces the Start of Patient Dosing In Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock
12/18/2023
Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT) today announced that the Company recently enrolled the first subject in its Phase 2 SEISMiC Extension Study of istaroxime in the treatment of early cardiogenic shock.
-
Windtree Therapeutics Announces Issuance of New Pure SERCA2a Activator Patent
11/16/2023
Windtree Therapeutics, Inc. today announced that the European Patent Office has granted Patent No. 3805243, providing composition of matter patent coverage for the pure SERCA2a Activator class of drug candidates.
-
Windtree Therapeutics Reports Third Quarter 2023 Financial Results and Provides Key Business Updates
11/9/2023
Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today reported financial results for the third quarter ended September 30, 2023 and provided key business updates.
-
Windtree to Present at the Sidoti Micro Cap Conference on November 16th
11/8/2023
Windtree Therapeutics, Inc. announced that Craig Fraser, President and Chief Executive Officer, will present a corporate update at the Sidoti Micro Cap Conference on Thursday, November 16, 2023 at 1:45pm ET.
-
Windtree to Present at the ThinkEquity Conference on October 19th in New York City
10/12/2023
Windtree Therapeutics, Inc. today announced that Craig Fraser, President and Chief Executive Officer, will be presenting at the upcoming ThinkEquity Conference on Thursday, October 19, 2023 at 4:30pm ET.
-
Windtree to Participate in the Lytham Partners Fall 2023 Investor Conference on October 17th
10/10/2023
Windtree Therapeutics, Inc. today announced that Craig Fraser, President and Chief Executive Officer, will be participating in a panel discussion titled, “Cardiac Kids: Late-Stage Advancement for Cardiovascular Disorders,” at the Lytham Partners Fall 2023 Investor Conference on Tuesday, October 17, 2023.
-
Windtree to Present at the Dawson James Small Cap Growth Conference on October 12th
10/3/2023
Windtree Therapeutics, Inc. announced that Craig Fraser, President and Chief Executive Officer, will be presenting at the upcoming Dawson James Small Cap Growth Conference on October 12, 2023 in Jupiter, FL.
-
Windtree Announces Issuance of Composition of Matter Patent for Dual Mechanism SERCA2a Activators by the US Patent and Trademark Office
8/23/2023
Windtree Therapeutics, Inc. reported that the United States Patent and Trademark Office has issued US Patent No. 11,730,746 covering the Company’s dual mechanism SERCA2a Activators.
-
Windtree Therapeutics Reports Second Quarter 2023 Financial Results and Provides Key Business Updates
8/7/2023
Windtree Therapeutics, Inc., a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, reported financial results for the second quarter ended June 30, 2023 and provided key business updates.
-
Windtree Therapeutics Appoints Mark Strobeck, Ph.D. to Board of Directors
6/27/2023
Windtree Therapeutics, Inc. today announced that the Company appointed Mark Strobeck, Ph.D. to its Board of Directors.
-
Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a Group of SERCA2a Activators with a Dual Mechanism
6/12/2023
Windtree Therapeutics, Inc., a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, reported that the United States Patent and Trademark Office has issued a Notice of Allowance for its patent application covering the Company’s dual mechanism SERCA2a Activators.
-
Windtree Therapeutics to Host Virtual R&D and Investor Day Focusing on the Cardiogenic Shock Market, Istaroxime, Company Strategy and Planned Near-Term Milestones
6/5/2023
Windtree Therapeutics, Inc., a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, announced it will host a virtual R&D and Investor Day on Wednesday, June 14, 2023 at 1:00 PM ET.
-
Windtree Therapeutics Reports First Quarter 2023 Financial Results and Provides Key Business Updates
5/15/2023
Windtree Therapeutics, Inc., a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, reported financial results for the first quarter ended March 31, 2023 and provided key business updates.
-
Windtree Therapeutics Announces Publication from Its SEISMiC Pre Cardiogenic Shock Study Comparing Two Doses of Istaroxime
4/27/2023
Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT) is a biotechnology company focused on advancing late-stage interventions for acute cardiovascular disorders of acute heart failure and a lead program studying istaroxime in cardiogenic shock.
-
Windtree Therapeutics Announces Closing of $12.42 Million Underwritten Public Offering Including Full Exercise of Overallotment Option
4/24/2023
Windtree Therapeutics, Inc., a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, announced the closing of its previously announced underwritten public offering of 3,686,006 shares of common stock, and warrants to purchase up to 3,686,006 shares of common stock.
-
Windtree Therapeutics Announces Pricing of Upsized $10.8 Million Underwritten Public Offering
4/20/2023
Windtree Therapeutics, Inc. today announced the pricing of its underwritten public offering of 3,686,006 shares of common stock and warrants to purchase up to 3,686,006 shares of common stock (the “Offering”).